MedC Biopharma and Sana Healthcare Partner to Advance Skin Oncology Platform
News provided by
Share this article
Share this article
TORONTO, Jan. 12, 2021 /PRNewswire/ MedC Biopharma Corporation ( MedC ), a Canadian clinical-stage biopharmaceutical company that develops and commercializes products containing cannabinoids and/or other natural compounds, is pleased to announce a strategic partnership agreement with Sana Healthcare ( Sana ). Sana is a specialist importer, wholesaler and distributor of cannabis-based medicines and supports biopharmaceutical companies in selecting and then pursuing the most appropriate clinic pathways in the UK. The partnership will advance the development of MedC s product platform for the treatment of Cutaneous T-Cell Lymphoma (CTCL) Sezary Syndrome.